Lisata Therapeutics Q3 2024 Earnings Report $2.71 +0.19 (+7.54%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Lisata Therapeutics EPS ResultsActual EPS-$0.59Consensus EPS -$0.75Beat/MissBeat by +$0.16One Year Ago EPS-$0.65Lisata Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALisata Therapeutics Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseLSTA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Lisata Therapeutics Earnings HeadlinesLisata Therapeutics complete enrollment in CENDIFOX trialDecember 11, 2024 | markets.businessinsider.comLisata Therapeutics Completes Enrollment for Cancer Therapy TrialDecember 11, 2024 | finance.yahoo.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 22, 2024 | Crypto 101 Media (Ad)Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnershipDecember 11, 2024 | proactiveinvestors.comLisata Therapeutics completes patient enrollment for CENDIFOX trialDecember 10, 2024 | proactiveinvestors.comLisata Therapeutics Announces Completion of Enrollment in the CENDIFOX TrialDecember 10, 2024 | globenewswire.comSee More Lisata Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lisata Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lisata Therapeutics and other key companies, straight to your email. Email Address About Lisata TherapeuticsLisata Therapeutics (NASDAQ:LSTA), a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.View Lisata Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
